Petros Pharmaceuticals annual r&d spending
2020
2021
2022
2023
2024
Petros Pharmaceuticals R&D Spending Growth & History (PTPI)
Petros Pharmaceuticals's r&d spending was $2.6M for fiscal 2024.
View full Petros Pharmaceuticals company overviewPetros Pharmaceuticals annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2024 | 2024-12-31 | $2.6M | $205,956 | +8.55% |
| 2023 | 2023-12-31 | $2.4M | $668,814 | +38.43% |
| 2022 | 2022-12-31 | $1.7M | −$48,211 | −2.70% |
| 2021 | 2021-12-31 | $1.8M | $1.3M | +289.11% |
| 2020 | 2020-12-31 | $459,636 | — | — |
Petros Pharmaceuticals quarterly r&d spending
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q4 2024 | 2024-12-31 | $101,944 | −$732,389 | −87.78% |
| Q3 2024 | 2024-09-30 | $588,355 | $199,262 | +51.21% |
| Q2 2024 | 2024-06-30 | $368,798 | −$497,777 | −57.44% |
| Q1 2024 | 2024-03-31 | $1.6M | $1.2M | +387.62% |
| Q4 2023 | 2023-12-31 | $834,333 | $656,571 | +369.35% |
| Q3 2023 | 2023-09-30 | $389,093 | −$346,823 | −47.13% |
| Q2 2023 | 2023-06-30 | $866,575 | $445,333 | +105.72% |
| Q1 2023 | 2023-03-31 | $319,093 | −$86,267 | −21.28% |
| Q4 2022 | 2022-12-31 | $177,762 | −$810,926 | −82.02% |
| Q3 2022 | 2022-09-30 | $735,916 | $455,340 | +162.29% |
| Q2 2022 | 2022-06-30 | $421,242 | −$78,804 | −15.76% |
| Q1 2022 | 2022-03-31 | $405,360 | $386,179 | +2013.34% |
| Q4 2021 | 2021-12-31 | $988,688 | $836,848 | +551.14% |
| Q3 2021 | 2021-09-30 | $280,576 | $243,748 | +661.86% |
| Q2 2021 | 2021-06-30 | $500,046 | $368,463 | +280.02% |
| Q1 2021 | 2021-03-31 | $19,181 | −$120,204 | −86.24% |
| Q4 2020 | 2020-12-31 | $151,840 | — | — |
| Q3 2020 | 2020-09-30 | $36,828 | — | — |
| Q2 2020 | 2020-06-30 | $131,583 | — | — |
| Q1 2020 | 2020-03-31 | $139,385 | — | — |
Petros Pharmaceuticals r&d spending trends
Between the periods ended 2020-12-31 and 2024-12-31, Petros Pharmaceuticals's r&d spending increased from $459,636 to $2.6M, a change of $2.2M. The latest reported quarter, Q4 2024, shows $101,944.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Petros Pharmaceuticals source filings ↗